Introduction {#cpf12539-sec-0005}
============

Peak oxygen uptake ($\overset{˙}{V}$O~2peak~), measured by a maximal cardiopulmonary exercise test (CPET) represents the upper limit of aerobic capacity. A low $\overset{˙}{V}$O~2peak~ is associated with the loss of independence in older individuals (Shephard, [2009](#cpf12539-bib-0038){ref-type="ref"}) and increased all‐cause and cardiovascular mortality in patients with coronary heart disease (CHD) (Keteyian *et al*., [2008](#cpf12539-bib-0020){ref-type="ref"}). The physiological factors that limit $\overset{˙}{V}$O~2peak~ are summarized by the Fick equation (Bassett & Howley, [2000](#cpf12539-bib-0004){ref-type="ref"}; Poole *et al*., [2012](#cpf12539-bib-0034){ref-type="ref"}; Lundby *et al*., [2017](#cpf12539-bib-0025){ref-type="ref"}):$$\overset{˙}{V}O_{2{peak}} = {\text{cardiac\ output}\, \times \,(a - \text{vO}_{2}}{\,\text{diff})}$$

Where *cardiac output* is the product of heart rate (HR) and stroke volume (SV), and *a*−vO~2~ diff is the difference between arterial and venous O~2~ content, representing muscle O~2~ extraction. In healthy individuals, $\overset{˙}{V}$O~2peak~ is limited centrally; maximum cardiac output limits O~2~ delivery to the exercising muscle at the rate that it is required for aerobic resynthesis of ATP (Bassett & Howley, [2000](#cpf12539-bib-0004){ref-type="ref"}; Lundby *et al*., [2017](#cpf12539-bib-0025){ref-type="ref"}). However, in patients with chronic heart failure (CHF), a cascade of events alters peripheral muscle physiology. These include, reduced skeletal muscle oxidative enzyme activity, reduced mitochondrial density, decreased perfusion matching with oxidative muscle fibres (Poole *et al*., [2012](#cpf12539-bib-0034){ref-type="ref"}) and decreased skeletal muscle mass (Cicoira *et al*., [2001](#cpf12539-bib-0011){ref-type="ref"}). Consequently, the peripheral muscle may become the primary limitation to $\overset{˙}{V}$O~2peak~ (Clark *et al*., [1996](#cpf12539-bib-0012){ref-type="ref"}; Shelton *et al*., [2010](#cpf12539-bib-0037){ref-type="ref"}; Poole *et al*., [2012](#cpf12539-bib-0034){ref-type="ref"}).

As CHF worsens, skeletal muscle mass (Collamati *et al*., [2016](#cpf12539-bib-0013){ref-type="ref"}) and $\overset{˙}{V}$O~2peak~ decline (Piepoli *et al*., [2006](#cpf12539-bib-0031){ref-type="ref"}; Fülster *et al*., [2013](#cpf12539-bib-0015){ref-type="ref"}). However, this relationship has not yet been reported in patients with CHD. Around a quarter of patients with CHD have low muscle mass and function (sarcopenia) (Harada *et al*., [2017](#cpf12539-bib-0017){ref-type="ref"}), compared with only 10% of adults older than 60 years (Shafiee *et al*., [2017](#cpf12539-bib-0036){ref-type="ref"}). Patients with CHD are commonly physically inactive which, together with progression of the underlying CHD, may exacerbate loss of muscle mass. Patients with CHD who experience a marked loss of skeletal muscle mass may have a reduced $\overset{˙}{V}$O~2peak~ and consequently higher risk of early mortality. Identifying the relationship between skeletal muscle mass and $\overset{˙}{V}$O~2peak~ in patients with CHD may be important so that preventative exercise and nutritional interventions can be developed.

We aimed to describe the association between skeletal muscle mass and $\overset{˙}{V}$O~2peak~ in male patients with CHD. We also assessed the relationship between skeletal muscle mass and other potentially important variables: peak oxygen pulse (peak $\overset{˙}{V}$O~2~/HR) (Laukkanen *et al*., [2006](#cpf12539-bib-0022){ref-type="ref"}), ventilatory anaerobic threshold (VAT) (Gitt *et al*., [2002](#cpf12539-bib-0016){ref-type="ref"}), $\overset{˙}{V}$E/$\overset{˙}{V}$CO~2~ slope (Van de Veire *et al*., [2006](#cpf12539-bib-0041){ref-type="ref"}), N‐terminal pro B‐type Natriuretic Peptide (NT‐proBNP) (Omland *et al*., [2007](#cpf12539-bib-0030){ref-type="ref"}) and CALIBER 5‐year all‐cause mortality risk (Rapsomaniki *et al*., [2014](#cpf12539-bib-0035){ref-type="ref"}).

Methods {#cpf12539-sec-0006}
=======

Study design {#cpf12539-sec-0007}
------------

Data for this cross‐sectional study included baseline measurements taken from male patients enrolled in the Cardiovascular and cardiorespiratory Adaptations to Routine Exercise‐based Cardiac Rehabilitation (CARE CR) study (Nichols *et al*., [2018](#cpf12539-bib-0029){ref-type="ref"}). Ethical approval was obtained from the Humber Bridge NHS Research Ethics Committee -- Yorkshire and the Humber (13/YH/0278). Study procedures conform to the declaration of Helsinki 1964.

The study protocol for CARE CR has previously been reported (Nichols *et al*., [2018](#cpf12539-bib-0029){ref-type="ref"}). Briefly, clinically stable male patients who had recently been discharged from hospital following an admission for stable angina, myocardial infarction (MI), coronary artery bypass graft (CABG) surgery or elective percutaneous coronary intervention (PCI) were recruited. Patients were asked to attend the research laboratory having not participated in strenuous exercise within the previous 24 h. Written informed consent was obtained prior to conducting any investigations.

Resting measurements {#cpf12539-sec-0008}
--------------------

Resting HR and left arm brachial blood pressure were taken at the end of 15 min semi‐supine rest using a 12‐lead ECG (GE Healthcare, Buckinghamshire, UK) and an ECG‐gated automated blood pressure cuff (Tango, SunTech Medical, Eynsham, UK). Stature (cm) was measured using a Leicester Height Measure (SECA, Birmingham, UK). Waist circumference measurements were taken 1 cm above the iliac crest, and hip measurements were taken from the widest aspect of the buttocks. Both measurements were recorded in cm, and the ratio of the two was calculated to determine waist‐to‐hip circumference ratio (ACSM [2017](#cpf12539-bib-0001){ref-type="ref"}).

A 2D echocardiogram was used to determine left ventricular (LV) function. LV ejection fraction (LVEF) was calculated using Simpson\'s method from measurements of end‐diastolic and end‐systolic volumes on apical four‐ chamber and two‐chamber 2D views, following the guidelines of Lang and colleagues (Lang *et al*., [2015](#cpf12539-bib-0021){ref-type="ref"}). LV systolic dysfunction was diagnosed if LVEF was ≤45%.

Body composition {#cpf12539-sec-0009}
----------------

Body composition was determined using dual X‐ray absorptometry \[DEXA\] (Lunar iDXA, 255 GE Healthcare). Total body mass (kg), lean body mass (kg) and total fat (%) were determined using the Lunar iDXA\'s integrated software. BMI (kg m^−2^) was calculated using DEXA‐derived total body mass. Appendicular lean mass (ALM; total lean mass in both arms and legs) was calculated (kg) and indexed to derive skeletal muscle index (SMI; measured in kg m^−2^). ALM was also reported as a percentage of total body mass (appendicular skeletal mass; ASM%). Low skeletal muscle mass was defined as an SMI of \<7·26 kg m^−2^ as recommended by international consensus guidelines (Cruz‐Jentoft *et al*., [2010](#cpf12539-bib-0014){ref-type="ref"}). A low ASM% was defined as \<25·72% (Levine & Crimmins, [2012](#cpf12539-bib-0023){ref-type="ref"}). This approach may be more appropriate for patients who are overweight/obese and have a higher absolute skeletal muscle mass, but low skeletal muscle mass relative to their total body mass.

Maximal cardiopulmonary exercise test {#cpf12539-sec-0010}
-------------------------------------

The cardiopulmonary exercise testing adhered to established guidelines and recommendations (American Thoracic Society/American College of Chest Physicians [2003](#cpf12539-bib-0002){ref-type="ref"}; Balady *et al*., [2010](#cpf12539-bib-0003){ref-type="ref"}; Nichols *et al*., [2015](#cpf12539-bib-0028){ref-type="ref"}; Taylor *et al*., [2015](#cpf12539-bib-0040){ref-type="ref"}) and was performed using the modified Bruce treadmill protocol (Bruce *et al*., [1973](#cpf12539-bib-0009){ref-type="ref"}) (GE Healthcare). A 12‐lead ECG was monitored continuously throughout the test. An ECG‐gated automated BP measurement was recorded at the start of the test and at the second minute of each test stage until the end of the test. Rating of perceived exertion (RPE) scores (6‐20) was recorded at peak exercise (Borg, [1982](#cpf12539-bib-0008){ref-type="ref"}). Breath‐by‐breath metabolic gas exchange data were collected using an Oxycon Pro metabolic cart (Jaeger, Hoechburg, Germany). $\overset{˙}{V}$O~2peak~ was defined as the mean $\overset{˙}{V}$O~2~ (ml) over the last 30 s of the test. $\overset{˙}{V}$O~2peak~ was also adjusted for body mass (ml kg^−1^ min^−1^). The VAT was analysed by two independent investigators using the V‐slope method (Beaver *et al*., [1986](#cpf12539-bib-0005){ref-type="ref"}) with data averaged over the middle five of seven consecutive breaths. The VAT was reported in ml, and standardized to patient body mass (ml kg^−1^ min^−1^). $\overset{˙}{V}$O~2~/HR (ml per beat) and $\overset{˙}{V}$E/ $\overset{˙}{V}$CO~2~ slope were calculated as previously described (Nichols *et al*., [2015](#cpf12539-bib-0028){ref-type="ref"}, [2018](#cpf12539-bib-0029){ref-type="ref"}).

Pulse wave velocity {#cpf12539-sec-0011}
-------------------

Pulse wave velocity (PWV) between the brachium and ankle was measured (Vascular Explorer, Enverdis GmbH, Düsseldorf, Germany) after 15 min of semi‐supine rest (torso elevated 45°) in a quiet temperature controlled room (21°C). A blood pressure cuff was placed proximally to the left cubital fossa (brachial artery) and another placed proximally to the medial malleolus. Photoplethysmographic sensors were placed on the patients left index finger and left hallux. Oscillations in the pulse waves alter the volume of the blood pressure cuff and are converted to a PWV. A shorter PWV (ms) indicates more severe arterial stiffness and/or worse peripheral vascular health. The reproducibility of PWV measurement at a single time point has been shown to be good (intraclass correlation 0·72--0·86) (Sutton‐Tyrrell *et al*., [2001](#cpf12539-bib-0039){ref-type="ref"}).

Blood samples {#cpf12539-sec-0012}
-------------

Resting venous blood samples were collected in ethylenediaminetetraacetic acid (EDTA), potassium oxalate and serum separating tubes (SST). EDTA and potassium oxalate tubes were spun in a refrigerated (4°C) centrifuge at 3000 revolutions per min, for 15 min immediately after the blood draw. Samples collected in SST tubes were allowed to clot for 30 min prior to being centrifuged under the same conditions. Haematocrit and haemoglobin concentrations, neutrophil and lymphocyte count, and NT‐proBNP were analysed using a registered National Health Service (NHS) pathology laboratory (Castle Hill Hospital, Hull). All samples not analysed on the day of collection were stored in a −80°C freezer. The ABX Pentra 400 biochemistry auto analyser (Horiba, Montpellier, France) was used to analyse serum plasma glucose, and high sensitivity C‐reactive protein (hs‐CRP) in duplicate. Calibration and quality controls were conducted in accordance with manufacturer\'s guidelines.

Prognosis -- Calibre 5‐year all‐cause mortality risk {#cpf12539-sec-0013}
----------------------------------------------------

Five‐year risk of all‐cause mortality was calculated for each patient using the comprehensive online (<https://www.caliberresearch.org/model>) Calibre 5‐year risk score (Rapsomaniki *et al*., [2014](#cpf12539-bib-0035){ref-type="ref"}). The Calibre risk score has been developed in a population of 100 000 patients with CHD. The model has good calibration and discrimination in internal and external validation (C‐Index 0·811) for all‐cause mortality. Importantly, the model does not include any fitness measurements in its calculation. Five‐year risk of all‐cause mortality was reported as a percentage. The variables included in the Calibre score are shown in Table [1](#cpf12539-tbl-0001){ref-type="table"}.

###### 

Variables included in the CALIBER 5‐year risk score

  Categorical variables                 Continuous variables
  ------------------------------------- ----------------------
  Sex                                   Age
  Belongs to most deprived quintile     Total cholesterol
  CAD diagnosis and severity            HDL
  Interventions (last 6 months)         Heart rate
  Smoking status                        Creatinine
  Hypertension/BP lowering medication   White cell count
  Diabetes                              Haemoglobin
  Heart failure                         
  Peripheral arterial disease           
  Atrial fibrillation                   
  Stroke                                
  Chronic renal disease                 
  COPD                                  
  Cancer                                
  Chronic liver disease                 
  Depression                            
  Anxiety                               

CAD, Coronary Artery Disease; BP, Blood Pressure; COPD, Chronic Obstructive Pulmonary Disease; HDL, High‐density Lipoprotein.
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Statistical analysis {#cpf12539-sec-0014}
--------------------

Statistical analysis was performed using SPSS version 22 (IBM, New York, NY, USA). The distribution of the data were assessed visually and using the Shapiro--Wilk test. Categorical data are reported as percentages. Continuous normally distributed variables are displayed as mean with 95% confidence intervals (95% CI) or standard deviation (±) where specified. Non‐normally distributed data are displayed as median (range). Pearson\'s (normally distributed), Spearman\'s correlations (non‐normally distributed) and age‐adjusted partial correlations were used to assess the relationship between indices of skeletal muscle mass and variables of interest. An *r* value of \<0·25, 0·26--0·50, 0·51--0·75, and, \>0·75 were considered weak, moderate, fair and strong associations, respectively (Berg & Latin, [2008](#cpf12539-bib-0007){ref-type="ref"}). Scatter plots of partial correlations were constructed using the residuals of the independent skeletal muscle indices and dependent variables. Where a variable was significantly associated with SMI or ASM%, receiver operating characteristic (ROC) curves were used to investigate the sensitivity and specificity of predicting low skeletal muscle mass. Patients with a low skeletal muscle mass (SMI \<7·26 Kg m^−2^ or ASM% \<25·72%) were treated as the dichotomous 'state‐variable' for the ROC curve. Statistical significance was set at *P* = 0·05.

Up to six dependent variables with the strongest, significant age‐adjusted partial correlations were selected for inclusion within separate stepwise multivariate regression models. The main outcome variables selected were $\overset{˙}{V}$O~2peak~, VAT, peak $\overset{˙}{V}$O~2~/HR, CPET duration, Calibre 5‐year all‐cause mortality risk and NT‐proBNP.

Results {#cpf12539-sec-0015}
=======

Sixty male patients (aged, 62·1 ± 10·0 years; BMI, 28·8 ± 3·7 kg m^−2^) were recruited. Patient characteristics, comorbidities and medications are reported in Tables [2](#cpf12539-tbl-0002){ref-type="table"}, [3](#cpf12539-tbl-0003){ref-type="table"} and [4](#cpf12539-tbl-0004){ref-type="table"}, respectively. Fifteen patients (25·0%) had sustained a ST‐elevation MI, 19 (31·7%) a non‐ST‐elevation MI, 16 (26·7%) underwent elective PCI, 6 (10·0%) CABG and 4 (6·7%) had exertional angina. Comorbidities are shown in Table [3](#cpf12539-tbl-0003){ref-type="table"}. Median time from cardiac event to baseline assessment was 54 days (range 22--220 days). Mean resting HR was 82 bpm ± 14 bpm. Mean resting systolic and diastolic blood pressure was 127 ± 17 mmHg and 58 ± 9 mmHg, respectively. Four patients (6·6%) had a LVEF \<45%, ten (16·7%) had an NT‐proBNP \>400 pg l^−1^ and one (1·7%) had an NT‐proBNP \>2000 pg l^−1^. The proportion of patients with low skeletal muscle mass was 16·7% by SMI and 11·7% by ASM%. However, only four patients had both a low SMI *and* ASM%, meaning that 13 (21·7%) had a low SMI *or* ASM%.

###### 

Patient characteristics

  Variable                                            Mean (±SD)
  --------------------------------------------------- ----------------------
  Age (Years)                                         63·1 (10·0)
  BMI (kg m^−2^)                                      28·8 (3·7)
  ALM (kg)                                            24·8 (4·0)
  SMI (kg m^−2^)                                      8·3 (1·1)
  ASM%                                                29·1 (2·5)
  Body fat%                                           35·5 (9·3)
  Waist/Hip ratio                                     0·98 (0·06)
  $\overset{˙}{V}$O~2peak~ (ml kg^−1^ min^−1^)        24·0 (5·6)
  $\overset{˙}{V}$O~2peak~ (ml)                       2079·3 (552·6)
  $\overset{˙}{V}$O~2peak~ Lean (ml kg^−1^ min^−1^)   38·5 (8·3)
  VAT (ml kg^−1^ min^−1^)                             17·2 (5·1)
  VAT (ml)                                            1481·9 (452·4)
  VAT Lean (ml kg^−1^ min^−1^)                        27·8 (7·6)
  Peak $\overset{˙}{V}$O~2~/HR (ml per beat)          15·5 (3·3)
  Peak HR (bpm)                                       134 (20)
  $\overset{˙}{V}$E/$\overset{˙}{V}$CO~2~ slope       34·3 (6·0)
  CPET duration (s)                                   826·6 (193·8)
  LVEF (%)                                            54·3 (6·7)
  Calibre 5‐year risk (%)                             8·3 (7·0)
  NT‐proBNP (pg l^−1^)                                174·5 (11·4--2735·0)
  hs‐CRP (mg l^−1^)                                   2·3 (3·0)
  Glucose (mmol l^−1^)                                6·1 (2·0)

BMI, body mass index; ALM, appendicular lean mass; SMI, skeletal muscle index; ASM%, appendicular skeletal mass; $\overset{˙}{V}$O~2peak~, peak oxygen uptake; VAT, ventilatory anaerobic threshold; $\overset{˙}{V}$O~2~/HR, oxygen pulse; HR, heart rate; bpm, bats per minute; $\overset{˙}{V}$E/$\overset{˙}{V}$CO~2~ slope, ventilatory efficiency with respect to carbon dioxide elimination; CPET, cardiopulmonary exercise test; LVEF, left ventricular ejection fraction; NT‐proBNP, N‐terminal pro B‐type natriuretic peptide; hs, high sensitivity.

John Wiley & Sons, Ltd

###### 

Patient comorbidities (Frequency)

  Comorbidity                          All patients
  ------------------------------------ --------------
  Hypertension (%)                     27 (45·0)
  Diabetes (%)                         11 (18·3)
  COPD (%)                             2 (3·3)
  Hyperlipidaemia (%)                  38 (63·3)
  Hypothyroidism                       5 (9·1)
  Previous PCI (%)                     13 (21·7)
  Previous MI (%)                      14 (23·4)
  Previous CABG (%)                    4 (6·7)
  Previous cardiac valve surgery (%)   1 (1·7)
  Previous CVA (%)                     6 (10·0)
  Previous Cancer                      8 (13·3)

COPD, chronic obstructive pulmonary disease; PCI, percutaneous coronary intervention; MI, myocardial infarction; CABG, coronary artery bypass graft; CVA, cerebrovascular accident.

John Wiley & Sons, Ltd

###### 

Patient medications (Frequency)

  Medications          All patients
  -------------------- --------------
  Aspirin (%)          58 (96·7)
  Clopidogrel (%)      16 (26·7)
  Ticagrelor (%)       33 (55·0)
  Beta‐Blockers (%)    54 (90·0)
  ACE Inhibitors (%)   38 (63·3)
  Statins (%)          57 (95·0)
  Diuretics (%)        5 (8·3)
  Nitrates (%)         13 (21·7)
  GTN (%)              54 (90·0)

ACE, angiotensin converting enzyme; GTN, glyceryl trinitrate.

John Wiley & Sons, Ltd

Correlations between ALM, SMI, ASM% and dependent variables of interest are presented in Table [5](#cpf12539-tbl-0005){ref-type="table"}. The associations between ALM, SMI and $\overset{˙}{V}$O~2peak~ (ml) were *r* = 0·566 (*P*\<0·001) and *r* = 0·473 (*P*\<0·001), respectively. The association between ASM% and $\overset{˙}{V}$O~2peak~ (ml kg^−1^ min^−1^) was *r* = 0·420 (*P* = 0·001). The strongest associations between indices of skeletal muscle mass and secondary outcome measures were observed between; ALM and peak $\overset{˙}{V}$O~2~/HR (*r* = 0·633; *P*\<0·001), SMI $\overset{˙}{V}$O~2~/HR (*r* = 0·575; *P*\<0·001) and ASM% and $\overset{˙}{V}$O~2peak~ \[ml kg^−1^ min^−1^\] (*r* = 0·431; *P*\<0·001). CPET variables that were significantly associated with ALM, SMI and ASM% are shown in Fig. [1](#cpf12539-fig-0001){ref-type="fig"}. ASM% was the only method of characterizing skeletal muscle mass resulting in a significant association with PWV, NT‐proBNP and Calibre 5‐year all‐cause mortality risk.

###### 

Correlation and partial correlations between appendicular lean mass, skeletal muscle index, appendicular skeletal mass and dependent variables

  Variable                                                      Appendicular lean mass   Skeletal muscle index                          Appendicular skeletal mass                                                                                                                                                                                                                                           
  ------------------------------------------------------------- ------------------------ ---------------------------------------------- ---------------------------- ------------------------------------------------ -------- ------------------------------------------------ -------- ------------------------------------------------ -------- ------------------------------------------------ -------- ----------------------------------------------
  $\overset{˙}{V}$O~2peak~ (ml)                                 0·666                    0·001[a](#cpf12539-note-0006){ref-type="fn"}   0·566                        \<0·001[a](#cpf12539-note-0006){ref-type="fn"}   0·577    \<0·001[a](#cpf12539-note-0006){ref-type="fn"}   0·473    \<0·001[a](#cpf12539-note-0006){ref-type="fn"}   0·225    0·084                                            0·205    0·130
  $\overset{˙}{V}$O~2peak~ (ml kg^−1^ min^−1^)                  0·189                    0·148                                          −0·007                       0·962                                            0·196    0·134                                            0·042    0·758                                            0·420    \<0·001[a](#cpf12539-note-0006){ref-type="fn"}   0·431    0·001[a](#cpf12539-note-0006){ref-type="fn"}
  VAT (ml)                                                      0·502                    0·001[a](#cpf12539-note-0006){ref-type="fn"}   0·360                        0·006[a](#cpf12539-note-0006){ref-type="fn"}     0·496    \<0·001[a](#cpf12539-note-0006){ref-type="fn"}   0·365    0·006[a](#cpf12539-note-0006){ref-type="fn"}     0·167    0·203                                            0·148    0·277
  VAT (ml kg^−1^ min^−1^)                                       0·053                    0·686                                          −0·092                       0·502                                            0·127    0·333                                            0·009    0·946                                            0·310    0·016[a](#cpf12539-note-0006){ref-type="fn"}     0·312    0·019[a](#cpf12539-note-0006){ref-type="fn"}
  Peak $\overset{˙}{V}$O~2~/HR (ml per beat)                    0·711                    0·001[a](#cpf12539-note-0006){ref-type="fn"}   0·633                        \<0·001[a](#cpf12539-note-0006){ref-type="fn"}   0·643    \<0·001[a](#cpf12539-note-0006){ref-type="fn"}   0·575    \<0·001[a](#cpf12539-note-0006){ref-type="fn"}   0·202    0·121                                            0·163    0·230
  Peak HR (bpm)                                                 0·165                    0·208                                          −0·042                       0·752                                            0·110    0·402                                            −0·073   0·581                                            0·076    0·565                                            0·026    0·845
  $\overset{˙}{V}$E/$\overset{˙}{V}$CO~2~ slope                 −0·272                   0·036[a](#cpf12539-note-0006){ref-type="fn"}   −0·078                       0·566                                            −0·270   0·037[a](#cpf12539-note-0006){ref-type="fn"}     −0·099   0·468                                            −0·195   0·135                                            −0·158   0·245
  CPET duration (s)                                             0·182                    0·165                                          0·014                        0·920                                            0·206    0·114                                            −0·047   0·730                                            0·376    0·003[a](#cpf12539-note-0006){ref-type="fn"}     0·399    0·022[a](#cpf12539-note-0006){ref-type="fn"}
  LVEF (%)                                                      0·153                    0·244                                          0·077                        0·574                                            0·137    0·297                                            0·068    0·620                                            0·076    0·566                                            0·055    0·698
  Calibre 5‐year risk (%)                                       −0·426                   0·001[a](#cpf12539-note-0006){ref-type="fn"}   −0·230                       0·870                                            −0·372   0·003[a](#cpf12539-note-0006){ref-type="fn"}     −0·224   0·098                                            −0·330   0·010[a](#cpf12539-note-0006){ref-type="fn"}     −0·365   0·006[a](#cpf12539-note-0006){ref-type="fn"}
  NT‐proBNP (pg l^−1^)[b](#cpf12539-note-0007){ref-type="fn"}   −0·295                   0·025[a](#cpf12539-note-0006){ref-type="fn"}   0·155                        0·254                                            −0·253   0·056                                            −0·131   0·337                                            −0·331   0·011[a](#cpf12539-note-0006){ref-type="fn"}     −0·326   0·014[a](#cpf12539-note-0006){ref-type="fn"}
  hs‐CRP(mg l^−1^)                                              −0·092                   0·486                                          −0·101                       0·458                                            0·000    0·999                                            −0·004   0·974                                            −0·193   0·140                                            −0·184   0·175
  Glucose (mmol l^−1^)                                          0·036                    0·789                                          −0·051                       0·708                                            0·135    0·314                                            0·065    0·634                                            −0·223   0·093                                            −0·242   0·073
  Body fat (%)                                                  0·149                    0·254                                          0·153                        0·261                                            0·151    0·249                                            0·148    0·275                                            −0·401   0·001[a](#cpf12539-note-0006){ref-type="fn"}     −0·406   0·002[a](#cpf12539-note-0006){ref-type="fn"}

corr., correlation; $\overset{˙}{V}$O~2peak~, peak oxygen uptake; VAT, ventilatory anaerobic threshold; $\overset{˙}{V}$O~2~/HR, oxygen pulse; HR, heart rate; bpm, beats per minute; $\overset{˙}{V}$E/$\overset{˙}{V}$CO~2~ slope, ventilatory efficiency with respect to carbon dioxide elimination; CPET, cardiopulmonary exercise test; LVEF, left ventricular ejection fraction; NT‐proBNP, N‐terminal pro B‐type natriuretic peptide; hs, high sensitivity.

Significant.

Spearman correlation.
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![Partial correlations between appendicular lean mass and $\overset{˙}{V}$ O ~2peak~ (a), VAT (b), and peak $\overset{˙}{V}$O~2~/HR (c). Panels d to f show partial correlations between skeletal muscle index and $\overset{˙}{V}$ O ~2peak~ (d), VAT (e) and peak $\overset{˙}{V}$ O ~2~/HR (f). Panels G to H show partial correlations between appendicular skeletal mass and $\overset{˙}{V}$ O ~2peak~ (g), VAT (h), and total CPET Duration (i). $\overset{˙}{V}$ O ~2peak~, peak oxygen uptake; VAT, ventilatory anaerobic threshold; $\overset{˙}{V}$ O ~2~/HR, oxygen pulse; CPET, cardiopulmonary exercise test. \* = Significant; + = Low muscle mass when defined using skeletal muscle index (\<7·26Kg m^−2^); ◊ = Low muscle mass when defined using appendicular skeletal mass (\<25·72%); ∆ = Low muscle mass when using either skeletal mass or appendicular skeletal mass.](CPF-39-93-g001){#cpf12539-fig-0001}

ROC curve analysis {#cpf12539-sec-0016}
------------------

Receiver operating characteristic curve analysis was conducted on variables that were significantly associated with measurements of SMI or ASM%. The area under the curve (AUC) for each prognostic variable is shown in Table [6](#cpf12539-tbl-0006){ref-type="table"}. For SMI, peak $\overset{˙}{V}$O~2~/HR had the greatest predictive capacity (AUC = 0·767; *P* = 0·008). Values \<13·3 ml per beat was predictive of a low SMI. When patients with a low SMI or ASM% were combined, peak $\overset{˙}{V}$O~2~/HR AUC was 0·764 (*P* = 0·004). A peak $\overset{˙}{V}$O~2~/HR \<14·3 ml per beat was most predictive of patients with a low SMI or ASM%. Patients with a NT‐proBNP \>112·5 pg l^−1^, a Calibre risk score \>3·0% or a modified Bruce treadmill duration \<17 min 43 s were also more likely to have a low ASM%.

###### 

Area under the curve for variables associated low skeletal muscle mass (95% confidence intervals)

  Variable                                       SMI                    ASM%                                           SMI & ASM%                                                                                   
  ---------------------------------------------- ---------------------- ---------------------------------------------- ---------------------- ---------------------------------------------- ---------------------- ----------------------------------------------
  $\overset{˙}{V}$O~2peak~ (ml)                  0·649 (0·478--0·820)   0·139                                          --                     --                                             0·675 (0·527--0·823)   0·055
  $\overset{˙}{V}$O~2peak~ (ml kg^−1 ^min^−1^)   --                     --                                             0·726 (0·510--0·943)   0·053                                          0·615 (0·430--0·810)   0·206
  Peak $\overset{˙}{V}$O~2~/HR (ml per beat)     0·767 (0·613--0·921)   0·008[a](#cpf12539-note-0009){ref-type="fn"}   --                     --                                             0·764 (0·632--0·895)   0·004[a](#cpf12539-note-0009){ref-type="fn"}
  VAT (ml)                                       0·594 (0·399--0·789)   0·351                                          --                     --                                             0·620 (0·455--0·786)   0·187
  VAT (ml kg^−1^ min^−1^)                        --                                                                    0·679 (0·454--0·904)   0·126                                          0·561 (0·368--0·755)   0·501
  CPET duration (s)                              --                                                                    0·744 (0·510--0·943)   0·037[a](#cpf12539-note-0009){ref-type="fn"}   0·648 (0·466--0·830)   0·104
  Calibre 5‐year risk (%)                        --                                                                    0·805 (0·600--1·00)    0·009[a](#cpf12539-note-0009){ref-type="fn"}   0·383 (0·191--0·574    0·202
  NT‐proBNP (pg l^−1^)                           --                                                                    0·759 (0·511--1·00)    0·027[a](#cpf12539-note-0009){ref-type="fn"}   0·623 (0·420--0·825)   0·178

SMI, skeletal muscle index; ASM%, appendicular skeletal mass; $\overset{˙}{V}$O~2peak~, peak oxygen uptake; $\overset{˙}{V}$O~2~/HR, oxygen pulse; VAT, ventilatory anaerobic threshold; CPET, cardiopulmonary exercise test; NT‐proBNP, N‐terminal pro B‐type natriuretic peptide.

Significant.

John Wiley & Sons, Ltd

Multivariate regression {#cpf12539-sec-0017}
-----------------------

Appendicular lean mass and age (both *P*\<0·001) were independent predictors of $\overset{˙}{V}$O~2peak~ (ml) and VAT (ml). For $\overset{˙}{V}$O~2peak~, these variables explained 58·8% of variance. For VAT 34·8% was explained. ALM alone accounted for 43·4% and 23·9% of variance for $\overset{˙}{V}$O~2peak~ and VAT, respectively. ALM was the only significant predictor of peak $\overset{˙}{V}$O~2~/HR (*P*\<0·001), accounting for 49·8% of variance.

Skeletal muscle index and age were independent predictors of $\overset{˙}{V}$O~2peak~ and the VAT (ml). For $\overset{˙}{V}$O~2peak~, 52·5% of variance was explained by SMI and age, with SMI accounting for 16·3%. For VAT, 35·8% of variance was explained by SMI and age. About 12·1% of variance was explained by VAT alone. Interestingly, only SMI was an independent predictor for peak $\overset{˙}{V}$O~2~/HR. 40·3% of variance was accounted for by $\overset{˙}{V}$O~2~/HR.

Similar to SMI, ASM% and age (both *P*\<0·001) were independent predictors of $\overset{˙}{V}$O~2peak~ and VAT, standardised to body mass (ml kg^−1^ min^−1^). 38·8% of $\overset{˙}{V}$O~2peak~ (ml kg^−1^ min^−1^) and 17·8% of VAT (ml kg^−1^ min^−1^) variance was accounted for by ASM% and age. ASM% alone accounted for 12·9% of $\overset{˙}{V}$O~2peak~ variance, compared to 6·3% for VAT. Age and ASM% were also independent predictors of NT‐proBNP (*P*\<0·001) with age accounting for 20·5% of NT‐proBNP variance and ASM% accounting for 7·2% (combined model; 27·2%). ASM% accounted for 9·4% of total Calibre 5‐year all‐cause mortality risk score variance (*P*\<0·001).

Discussion {#cpf12539-sec-0018}
==========

To our knowledge, this is the first study to investigate the relationship between skeletal muscle mass and $\overset{˙}{V}$O~2peak~ in patients with CHD. We identified that a lower skeletal muscle mass was associated with a lower $\overset{˙}{V}$O~2peak~, an observation previously reported in patients with CHF (Cicoira *et al*., [2001](#cpf12539-bib-0011){ref-type="ref"}). We also investigated the relationship between other important prognostic indicators, including peak $\overset{˙}{V}$O~2~/HR. Our data suggest that skeletal muscle mass may be more closely associated with peak $\overset{˙}{V}$O~2~/HR, rather than $\overset{˙}{V}$O~2peak~. Similar to previously reported data in patients with CHD (Harada *et al*., [2017](#cpf12539-bib-0017){ref-type="ref"}), we found that more than one‐fifth of patients had a low skeletal muscle mass; a higher proportion than reported among adults over the age of 60 years (10%) (Shafiee *et al*., [2017](#cpf12539-bib-0036){ref-type="ref"}). A lower skeletal muscle mass was associated with a higher 5‐year all‐cause mortality risk.

Peak oxygen uptake {#cpf12539-sec-0019}
------------------

Sarcopenia and/or a low muscle mass are associated with increased mortality risk (Cawthon *et al*., [2007](#cpf12539-bib-0010){ref-type="ref"}) and difficulties performing daily activities (Janssen, [2006](#cpf12539-bib-0019){ref-type="ref"}). A low $\overset{˙}{V}$O~2peak~ is also associated with a higher mortality risk (Keteyian *et al*., [2008](#cpf12539-bib-0020){ref-type="ref"}) and difficulties performing daily activities (Shephard, [2009](#cpf12539-bib-0038){ref-type="ref"}). Consistent with data reported on patients with CHF (*r* = 0·46 to *r* = 0·70) (Cicoira *et al*., [2001](#cpf12539-bib-0011){ref-type="ref"}; Piepoli *et al*., [2006](#cpf12539-bib-0031){ref-type="ref"}), we found that ALM was positively associated with $\overset{˙}{V}$O~2peak~ (*r* = 0·566). Although dependent on the methods used to scale $\overset{˙}{V}$O~2peak~, this relationship was maintained when ALM was standardized to stature (SMI; *r* = 0·473) and body mass (ASM%; *r* = 431). However, whilst ALM (43·4%), SMI (16·3%) and ASM% (12·9%) were independent predictors of $\overset{˙}{V}$O~2peak~, we were unable to replicate the same predictive strength (54‐65%) reported by Cicoira, *et al*. in non‐cachexic patients with CHF. This may be because patients with CHF can have severe skeletal muscle abnormalities (Clark *et al*., [1996](#cpf12539-bib-0012){ref-type="ref"}; Vescovo *et al*., [1996](#cpf12539-bib-0042){ref-type="ref"}; Piepoli *et al*., [2010](#cpf12539-bib-0032){ref-type="ref"}; Poole *et al*., [2012](#cpf12539-bib-0034){ref-type="ref"}) that limit exercise tolerance as a consequence of the disease (Shelton *et al*., [2010](#cpf12539-bib-0037){ref-type="ref"}). Given that CHD represents an earlier stage of cardiovascular dysfunction than CHF, skeletal muscle abnormalities may occur at an earlier stage of cardiovascular dysfunction. Skeletal muscle mass may therefore play a greater role in limiting $\overset{˙}{V}$O~2peak~ among patients with CHF, compared with patients who have CHD. Our observation may suggest that adverse changes in skeletal muscle mass and quality associated with cardiovascular dysfunction exist on a continuum. If this were true, early optimization strategies that target peripheral muscle in addition to cardiac function may be important for disease prevention.

Peak $\overset{˙}{V}$O~2~/HR was most closely associated with indices of skeletal muscle mass. ALM and SMI separately accounted for 49·8% and 40·3% of the variance in peak $\overset{˙}{V}$O~2~/HR, respectively. These indices of skeletal muscle mass not only had a stronger association with peak $\overset{˙}{V}$O~2~/HR (*r* = 0·575 to *r* = 0·633) compared to $\overset{˙}{V}$O~2peak~ (*r* = 0·566), but also had the largest AUC (0·767; 95% CI 0·613--0·921; *P* = 0·008). Unlike $\overset{˙}{V}$O~2peak,~ peak $\overset{˙}{V}$O~2~/HR had good sensitivity and specificity for detecting patients with a low SMI. A threshold of 13·3 ml per beat was identified as the point below which, patients were more likely to have a low SMI (7·26 kg m^−2^). Simple rearrangement of the Fick equation means that peak $\overset{˙}{V}$O~2~/HR becomes independent of HR; a factor that we (*r* = −0·042, −0·073, 0·026; *P*\>0·05 for all) and others (Horwich *et al*., [2009](#cpf12539-bib-0018){ref-type="ref"}; Piepoli *et al*., [2017](#cpf12539-bib-0033){ref-type="ref"}) have found to be unrelated to skeletal muscle. Instead, reported peak $\overset{˙}{V}$O~2~/HR characterizes SV and a‐vO~2~ difference (peripheral O~2~ extraction) which may explain why it appears to be more closely related to skeletal muscle mass than $\overset{˙}{V}$O~2peak~, in patients with CHD. However, whilst skeletal muscle mass has previously been identified as an independent predictor of peak $\overset{˙}{V}$O~2~/HR (74%) in hypertensive men and women (Lim *et al*., [2005](#cpf12539-bib-0024){ref-type="ref"}), the association between peak indices of skeletal muscle mass and peak $\overset{˙}{V}$O~2~/HR in our study was smaller \[40·3--49·8%\] (Lim *et al*., [2005](#cpf12539-bib-0024){ref-type="ref"}). Nonetheless, this is an interesting finding and should be further explored in a larger cohort.

The weaker relationship between indices of skeletal muscle mass and peak $\overset{˙}{V}$O~2~/HR observed in our study may indicate that patients with CHD have a different physiological response to maximal exercise, compared to patients with hypertension. Under normal circumstances, $\overset{˙}{V}$O~2~/HR rises progressively throughout an incremental exercise test until it reaches a plateau associated with normal physiological limitation to exercise (Whipp *et al*., [1996](#cpf12539-bib-0043){ref-type="ref"}). However, in patients with CHD, $\overset{˙}{V}$O~2~/HR may prematurely decrease during incremental exercise due to ischaemia‐induced myocardial wall‐motion abnormalities which cause a reduction in SV (Belardinelli *et al*., [2003](#cpf12539-bib-0006){ref-type="ref"}). This is thought to occur prior to ST‐segment changes detected using electrocardiogram, or symptoms of angina (Nesto & Kowalchuk, [1987](#cpf12539-bib-0027){ref-type="ref"}). If myocardial blood flow is not restored through surgical or medical intervention, $\overset{˙}{V}$O~2~/HR would be lower than expected at peak exercise and may attenuate the association between $\overset{˙}{V}$O~2~/HR, a‐vO~2~ difference and skeletal muscle mass. Alternatively, a low peak $\overset{˙}{V}$O~2~/HR may indicate greater cardiac dysfunction and consequently, more severe skeletal muscle abnormalities. However, whilst we cannot confirm either of these scenarios, peak $\overset{˙}{V}$O~2~/HR was a better predictor of SMI than any other measured variable, including $\overset{˙}{V}$O~2peak,~ the gold‐standard measurement of aerobic exercise capacity. Formal screening for sarcopenia in patients who are incidentally found to have a low peak $\overset{˙}{V}$O~2~/HR may be beneficial.

Prognostically important associations with skeletal muscle mass {#cpf12539-sec-0020}
---------------------------------------------------------------

Although SMI was associated with peak $\overset{˙}{V}$O~2~/HR, ASM% was not. However, ASM% was inversely associated with prognostically important variables including; $\overset{˙}{V}$O~2peak,~ PWV, 5‐year all‐cause mortality risk, a higher NT‐proBNP and, body fat percentage even when controlling for age. Although not specifically investigated by our study, the faster PWV speeds observed among patients with a lower SMI indicates more severe arterial stiffness and greater abnormalities in peripheral cardiovascular health, something reported among patients with CHF (Poole *et al*., [2012](#cpf12539-bib-0034){ref-type="ref"}). Furthermore, the higher NT‐proBNP values reported among patients with a lower ASM% suggests more advanced CHD, or the early development of CHF which may exacerbate the loss of skeletal muscle mass (Collamati *et al*., [2016](#cpf12539-bib-0013){ref-type="ref"}). The association between higher body fat percentage and relative lower skeletal muscle mass may also indicate the onset of sarcopenic obesity, fat infiltration of skeletal muscle and therefore reduced muscle quality (Narici & Maffulli, [2010](#cpf12539-bib-0026){ref-type="ref"}).

Strengths and weaknesses {#cpf12539-sec-0021}
------------------------

This is the first study to use gold‐standard measurement techniques (DXA and CPET) to investigate the relationship between low skeletal muscle mass and reduced aerobic exercise capacity in CHD patients. In addition, this study included a representative cohort of male patients with CHD and the statistical methods employed controlled for several variables that are commonly associated with reduced skeletal muscle mass and aerobic exercise capacity. However, this study has limitations; first, we did not assess muscle function, which meant that we could not report the prevalence of sarcopenia in our cohort. Second, our findings in our male only cohort may not be relevant to females with CHD. In addition, the sample size used in this population was relatively small. Finally, whilst the associations identified in our cross‐sectional cohort study are interesting, a prospective long‐term follow‐up study is required. This would help to determine whether progression of CHD confers with reduced skeletal muscle mass and whether this relates to prognostically important variables and/or the development of CHF.

Conclusion {#cpf12539-sec-0022}
==========

We found a high incidence of low skeletal muscle mass in our cohort of patients with CHD. When standardized to body mass (ASM%), low skeletal muscle mass conferred a higher predicted risk of all‐cause mortality. Low skeletal muscle mass was associated with a low $\overset{˙}{V}$O~2peak~ in patients with CHD; however, the relationship was complex and dependent on the method used to scale skeletal muscle mass and $\overset{˙}{V}$O~2peak~. Interestingly, our data show that there was a stronger association between SMI and peak $\overset{˙}{V}$O~2~/HR. The relationship between low skeletal muscle mass, prognostic indices and aerobic fitness suggests that adverse changes in skeletal muscle mass may be initiated before the diagnosis or development of CHF. These findings may highlight a need for preventative exercise and nutritional strategies to improve skeletal muscle mass and quality in patients with CHD.
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